Last reviewed · How we verify

Azilsartan medoxomil and olmesartan — Competitive Intelligence Brief

Azilsartan medoxomil and olmesartan (Azilsartan medoxomil and olmesartan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Azilsartan medoxomil and olmesartan (Azilsartan medoxomil and olmesartan) — Takeda. This combination of two angiotensin II receptor blockers (ARBs) blocks the angiotensin II type 1 receptor to reduce blood pressure and provide cardiovascular protection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azilsartan medoxomil and olmesartan TARGET Azilsartan medoxomil and olmesartan Takeda phase 3 Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
placebo/valsartan placebo/valsartan Medical University of Silesia marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
pravastatin, valsartan, pravastatin+valsartan pravastatin, valsartan, pravastatin+valsartan Gachon University Gil Medical Center marketed Statin + Angiotensin II Receptor Blocker (ARB) combination HMG-CoA reductase (pravastatin); Angiotensin II Type 1 receptor (valsartan)
losartan/amlodpine losartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB) Angiotensin II receptors (AT1) and L-type calcium channels
Valsartan (-based therapy) arm Valsartan (-based therapy) arm Hippocration General Hospital marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE Novartis marketed Angiotensin II receptor blocker (ARB) + thiazide diuretic AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)
Irbesartan Oral Tablet Irbesartan Oral Tablet University of Southern Denmark marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

  1. Chong Kun Dang Pharmaceutical · 2 drugs in this class
  2. Baker Heart and Diabetes Institute · 2 drugs in this class
  3. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  4. Lee's Pharmaceutical Limited · 2 drugs in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. Guangdong Provincial People's Hospital · 1 drug in this class
  7. Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
  8. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
  9. Bayer · 1 drug in this class
  10. Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azilsartan medoxomil and olmesartan — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan-medoxomil-and-olmesartan. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: